Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04308590 · ClinicalTrials.gov registry record · Phase 3
A Study of the Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas
A Phase 3 study of Hypercortisolism, sponsored by Corcept Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 137
- Enrollment target
- 20
- Study locations
NCT04308590: Completed Phase 3 study of Hypercortisolism, sponsored by Corcept Therapeutics.
NCT04308590 is a Phase 3 study of Hypercortisolism that has completed, run by Corcept Therapeutics. The registered enrollment target is 137 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (82% lower). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04308590, a Phase 3 study of Hypercortisolism, has completed, sponsored by Corcept Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 137 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 3, randomized, double-blind, placebo-controlled study to assess the efficacy, and safety of relacorilant to treat hypercortisolism in patients with cortisol-secreting adrenal adenoma or hyperplasia associated with diabetes mellitus/ impaired glucose tolerance (DM/IGT) and/or uncontrolled systolic hypertension (HTN).
Primary Outcome
Blood pressure was measured by 24-hour ABPM. The 24-hour average SBP is reported.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Relacorilant
Study Locations (20)
Texas
- Site 20 - Dallas
- Site 03 - El Paso
- Site 05 - Fort Worth
California
- Site 17 - Stanford
- Site 53 - Torrance
New York
- Site 10 - Jamaica
- Site 44 - New York
Ohio
- Site 30 - Cleveland
- Site 21 - Columbus
Alabama
- Site 27 - Birmingham
Georgia
- Site 07 - Atlanta
Indiana
- Site 16 - Indianapolis
Louisiana
- Site 09 - Metairie
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 137 participants |
| Start Date | 2020-07-27 |
| Est. Completion | 2024-09-19 |
| Phase | Phase 3 |
What the finished NCT04308590 record still lists
NCT04308590 is an interventional study that assigns participants to a tested intervention. The registered 137 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (82% lower).
The record links to 1 condition, with Hypercortisolism appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04308590 names 20 study sites across 15 states, led by Texas, California, New York.
Frequently Asked Questions
What is clinical trial NCT04308590 about?
NCT04308590 is a clinical study titled "A Study of the Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas". This is a Phase 3, randomized, double-blind, placebo-controlled study to assess the efficacy, and safety of relacorilant to treat hypercortisolism in patients with cortisol-secreting adrenal adenoma or hyperplasia associated with diabetes mellitus/ impaired glucose tolerance (DM/IGT) and/or uncontro...
What is the current status of trial NCT04308590?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 137 participants. The study started on 2020-07-27. Estimated completion is 2024-09-19.
What conditions does trial NCT04308590 study?
This clinical trial studies the following conditions: Hypercortisolism.
What interventions are being tested in trial NCT04308590?
The interventions under investigation include: Placebo (OTHER), Relacorilant (DRUG).
Who is sponsoring clinical trial NCT04308590?
This trial is sponsored by Corcept Therapeutics, which has 54 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04308590 being conducted?
This trial has 20 study locations across Alabama, California, Georgia, Indiana, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypercortisolism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04308590's enrollment target sits among peer trials
137 1580th of 2000 higher than 421 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05091424 · 137 participants · Phase 1
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
- NCT05655182 · 137 participants · Phase 1
A Study of BLB-201 RSV Vaccine in Infants and Children
- NCT06571669 · 137 participants · NA
BOOM-IBD2 Pivotal Clinical Trial
- NCT06644768 · 137 participants · Phase 1
A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI